HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. (HKMPF) Stock Price, Quote, News & History

Key Statistics

Open

Volume / Avg.

0 / 1.42K

Day Range

- - -

52 Wk Range

16.34 - 25.34

Market Cap

P/E Ratio

12.61

Dividend Yield

3.88%

Exchange

OTC

RSI

Short Interest

Days to Cover

999.99

Recent Hikma Pharmaceuticals PLC News

Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production

Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally.

Vandana Singh

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices

Jazz Pharmaceuticals and Hikma Pharmaceuticals will face trial over allegations of delaying a generic version of Xyrem, causing higher drug prices. Plaintiffs accuse Jazz of antitrust violations and claim the company raised Xyrem's price by over 800%.

Vandana Singh

Drug Shortages in Focus: How FDA's Quest for New Methotrexate Suppliers Affects the Cancer Treatment Landscape

The FDA is actively seeking new suppliers to address the shortages of methotrexate, a widely used cancer drug in short supply since March. Methotrexate is an injected medication utilized to treat various cancers and autoimmune diseases like rheumatoid arthritis, as stated by the National Cancer Institute.

Vandana Singh

A Peek Into The Markets: US Stock Futures Mostly Higher; Crude Oil Rises Over 1%

Pre-open movers

Lisa Levin

Hikma Bolsters Injectable Portfolio With $375M Custopharm Acquisition

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

489.00M

Investing Cash Flow (TTM)

-323.00M

Financing Cash Flow (TTM)

-138.00M

Free Cash Flow (TTM)

191.00M

Capital Expenditure (TTM)

-298.00M

Net Change in Cash (TTM)

28.00M

Valuation Metrics

Enterprise Value

$6.09B

PE Ratio (TTM)

12.61

PE Ratio (FWD)

8.73

PEG Ratio (TTM)

PS Ratio (TTM)

1.43

PB Ratio (TTM)

1.82

Earnings Yield % (TTM)

7.93%

Earnings Yield % (FWD)

11.46%

EV / EBITDA (TTM)

7.05

Price / EBITDA (TTM)

5.67

Price / Free Cash Flow (TTM)

25.65

Book Value / Share

$12.19

Company Debt

Total Debt

$1.87B

LT Debt

$1.68B

LT Debt Issuance (TTM)

$2.55B

LT Debt Repayment (TTM)

-$2.17B

Total Cash

$263.00M

Debt to Equity

0.78

Issuance of Debt (TTM)

$378.00M

Repayment of Debt (TTM)

-$2.53B

Key Statistics

Open

Volume / Avg.

0 / 1.42K

Day Range

- - -

52 Wk Range

16.34 - 25.34

Market Cap

P/E Ratio

12.61

Dividend Yield

3.88%

Exchange

OTC

RSI

Short Interest

Days to Cover

999.99

About

Sector

Health Care

Industry

Pharmaceuticals

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the compan...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

HKMPF

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

HKMPF

FAQ

How do I buy HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. (HKMPF) stock?

You can purchase shares of HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. (OTCPK:HKMPF) through any online brokerage.

View our list of the best stock brokerages

Who are HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. (HKMPF) competitors?

There are no as such competitors for HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc..

What is the forecast, or price target, for HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. (HKMPF) stock?

There is no analysis for HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. to provide a consensus price target.

What is the current price for HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. (HKMPF)?

The stock price for HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. (OTCPK: HKMPF) is $22.187 last updated August 17, 2026 at 10:28 AM EDT.

Does HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. (HKMPF) pay a dividend?

There are no upcoming dividends for HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc..

When is HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. (OTCPK:HKMPF) reporting earnings?

HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. does not have any upcoming earnings scheduled.

Is HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. (HKMPF) going to split?

There is no upcoming split for HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc..

What sector and industry does HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. (HKMPF) operate in?

HIKMA PHARMACEUTICALS PLC by Hikma Pharmaceuticals plc. is in the Health Care sector and Pharmaceuticals industry. They are listed on the OTCPK.